Roularta (ROU)
Euronext Brussels · Belgium · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 11.40 |
|---|---|
| 52-week range | 11.30 – 14.05 |
| Return, 1 month / 3 months | −6.6% / −14.0% |
| Return, 1 year / 3 years | −10.9% / +19.1% |
| Trend | Below its 200-day average |
| RSI (14) | 36 |
| Volatility (1 year) | 36.7% |
| Worst drawdown (1 year) | -18.0% |
| Average daily value traded | 0.00M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Roularta Media Group is a Belgian media company based in Roeselare. It publishes magazines and newspapers for Dutch-speaking and French-speaking readers in Belgium, with titles covering news, business and lifestyle topics, and it also produces free local papers distributed to households. Alongside print, the company operates in radio and television and provides printing and publishing services, serving advertisers and general audiences across the country.
The shares are listed on the Euronext Brussels in Belgium under the code ROU, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Roularta (ROU) trades on the Euronext Brussels in Belgium. It last closed at EUR 11.40 on 22 October 2026.
Its price-based Market X-Ray is 36 out of 100 (a weak price profile), ranking 83 of 111 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 10.9% and over the last three months it fell 14.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Brussels
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 38 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -11.3% | ||
| From 52-week high | -18.0% | ||
| Momentum | 30 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -14.0% | ||
| 6-month return | -13.0% | ||
| 12-month return, skipping the last month | -4.7% | ||
| Stability (higher is calmer) | 51 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 36.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -18.0% | ||
| Liquidity | 15 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M EUR | ||
| Zero-volume days | 5.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −3.4% |
|---|---|
| 1 month | −6.6% |
| 3 months | −14.0% |
| 6 months | −13.0% |
| 1 year | −10.9% |
| 3 years | +19.1% |
| 5 years | −4.4% |
Signals
| 50-day / 200-day average | 12.20 / 12.85 |
|---|---|
| Golden / death cross (60 days) | Death, 47 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.20 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 6 Aug 2025 | EUR 2.1000 |
| 22 May 2024 | EUR 0.7000 |
| 30 May 2023 | EUR 0.7000 |
| 30 May 2022 | EUR 0.7000 |
| 28 May 2021 | EUR 0.7000 |
| 30 May 2019 | EUR 0.3500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Brussels; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.